ClinicalTrials.gg
Active, not recruitingNCT07332494DigiCare-CHDUpdated Nov 20, 2026

Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)

An interventional study of Digital Remote Management Group in Coronary Heart Disease and Percutaneous Coronary Intervention, sponsored by Beijing Anzhen Hospital. Active, not recruiting at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now Active, not recruitingStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Coronary Disease by Beijing Anzhen Hospital — 4 open to participants now, 6 under way, none of them phase 3. Coronary Disease · Beijing Anzhen Hospital.

Started
2026
with 1 other
No phase
7 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Coronary Disease by Beijing Anzhen Hospital, this one is one of 2 that started in 2026, is one of 7 with no phase, and was the 11th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

4 of the 13 studies in Coronary Disease by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Coronary Disease by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluate the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.

Read the detailed description

"Coronary heart disease (CHD) remains a leading cause of global mortality. While percutaneous coronary intervention (PCI) significantly improves acute survival, patients continue to face substantial residual cardiovascular risk driven by the progression of systemic atherosclerosis. Rigorous management of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) is imperative for secondary prevention. However, achieving simultaneous targets (BP \< 130/80 mmHg and LDL-C \< 1.4 mmol/L) in real-world practice is challenging due to clinical inertia and suboptimal patient adherence. Traditional outpatient follow-up is often fragmented and reactive, failing to provide the continuous monitoring required for optimal risk factor control.

The DigiCare-CHD trial serves as a prospective, multicenter, open-label randomized controlled trial designed to enroll 792 patients who have successfully undergone PCI for acute or chronic coronary syndromes. Participants will be randomized 1:1 to either the Digital Remote Management group or the Usual Care group, with a follow-up period of 12 months.

Patients in the intervention arm will utilize a digital remote management platform. This system integrates home blood pressure monitoring, laboratory lipid results, medication adherence records, and patient-reported symptoms. Key features include AI-driven alerts for abnormal values, automated decision support for medication titration (verified by physicians), and targeted health education. The primary endpoint is the rate of dual goal attainment for BP and LDL-C at 12 months. DigiCare-CHD aims to establish a proactive, closed-loop management strategy to effectively reduce residual cardiovascular risk and improve long-term prognosis in the post-PCI population."

03

Conditions studied

  • Coronary Heart Disease
  • Percutaneous Coronary Intervention

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years
  2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS)
  3. Status post-successful percutaneous coronary intervention (PCI).
  4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance).
  5. Provision of written .

Exclusion criteria

Exclusion Criteria:

  1. Heart Failure: Class III-IV or \< 35%.
  2. Severe hepatic dysfunction (/AST ≥3xULN or Total >1.5 mg/dl)
  3. Severe renal dysfunction ( \< 30 ml/min/1.73m² or requiring dialysis)
  4. Uncontrolled hypothyroidism (TSH >1.5xULN or >10 mIU/L, or unstable dosage within 6 weeks)
  5. Other serious comorbid conditions with a of less than 1 year.
  6. Severe sensory (hearing/vision) or cognitive impairment precluding device use
  7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)
  8. Patients judged by the investigator to have poor adherence to the intervention.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
792 participants (actual)

Study arms

  • No intervention
    Usual care Group

    Patients receive standard post-PCI management, including guideline-directed medical therapy (GDMT), routine health education, and follow-up at 3, 6, and 12 months after randomization (each within a ±14-day window), conducted in person or remotely.

  • Experimental
    Digital Remote Management Group

    1-year intervention: 1. BP Management: Protocol-driven self-monitoring frequencies. The system triggers alerts for BP \>130/80 mmHg and generates automated suggestions for medication titration, subject to physician approval. 2. Lipid Management: Automated reminders for laboratory testing. Optical Character Recognition (OCR) technology extracts data from lab reports. If LDL-C ≥1.4 mmol/L, the system proposes regimen intensification for physician review. 3. Exercise Management: Target of ≥6000 steps/day. Data is synchronized via wearables or smartphones. Inactivity triggers automated behavioral feedback. 4. Medication Management: Daily app-based reminders and digital "check-ins." Non-adherence triggers automated alerts followed by human intervention if persistent. 5. Symptom Monitoring: Patient-reported outcomes (e.g., chest pain/dyspnea) via the App, with automated triage for risk stratification. 6. Health Education: Push delivery of targeted secondary prevention educational materials.

    Other: Digital Remote Management Group

Interventions

  • OtherDigital Remote Management Group

    1-year intervention 1. BP Management: Protocol-driven self-monitoring frequencies. The system triggers alerts for BP \>130/80 mmHg and generates automated suggestions for medication titration, subject to physician approval. 2. Lipid Management: Automated reminders for laboratory testing. Optical Character Recognition (OCR) technology extracts data from lab reports. If LDL-C ≥1.4 mmol/L, the system proposes regimen intensification for physician review. 3. Medication Management: Daily app-based reminders and digital "check-ins." Non-adherence triggers automated alerts followed by human intervention if persistent. 4. Symptom Monitoring: Patient-reported outcomes (e.g., chest pain/dyspnea) via the App, with automated triage for risk stratification. 5. Health Education: Push delivery of targeted secondary prevention educational materials.

06

What researchers measure

Primary outcomes

  1. Rate of Dual Goal Attainment for Blood Pressure and Lipids

    Defined as the proportion of patients achieving both SBP \< 130 mmHg and DBP \< 80 mmHg and LDL-C \< 1.4 mmol/L.

    Time frame: 12 months after randomization

Secondary outcomes

  1. Change in Left Ventricular Ejection Fraction (LVEF)

    Time frame: Baseline and 12 Months

  2. Medication Adherence

    Medication adherence assessed using the 10-item Medication Adherence Rating Scale (MARS-10). Total scores range from 0 to 10, with higher scores indicating better adherence.

    Time frame: 12 Months

  3. Smoking Cessation Rate

    Self-reported complete abstinence from smoking among baseline smokers

    Time frame: 12 Months

  4. Quality of Life(EQ-5D-5L)

    EQ-5D-5L

    Time frame: 12 Months

  5. Major Adverse Cardiovascular Events (MACE) Composite of all-cause death, myocardial infarction, malignant arrhythmia, or hospitalization for heart failure.

    Time frame: 12 Months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 19 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jan 2026 → Feb 2026, primary completion Jul 2027 → Oct 2027 and completion Jul 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartActual
Feb 27, 2026was Jan 2026
Primary completionEst.
Oct 10, 2027was Jul 2027
CompletionEst.
Oct 10, 2027was Jul 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 20, 2026
Sites
3 sites added, 2 sites removed
Show 3 added (3 China)
  • Beijing Anzhen Hospital, Capital Medical University · Beijing, China
  • The First Hospital of Jilin University, Changchun, China · Changchun, China
  • The Second Affiliated Hospital of Nanchang University · Nanchang, China
Show 2 removed
  • 13810720787 · Beijing, China
  • The First Hospital of Jilin University, Changchun, China · Jilin City, China
Nov 20, 2026
Start date
Jan 2026→Feb 27, 2026 (actual)
Nov 20, 2026
Primary completion
Jul 2027→Oct 10, 2027
Nov 20, 2026
Study completion
Jul 2027→Oct 10, 2027
Nov 20, 2026
Eligibility
Maximum age 75 Years→80 Years; 1 inclusion criterion edited; 2 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedAge 18-7580 years
Exclusion criteria
  • EditedHeart Failure: NYHA Class III-IV or LVEF < 4035%.
  • ChangedBefore Life expectancy < 1 year due to non-cardiovascular comorbiditiesNow Other serious comorbid conditions with a life expectancy of less than 1 year.
  • AddedPatients judged by the investigator to have poor adherence to the intervention.
Nov 20, 2026
Secondary outcomes
1 removed, 1 description edited
What changed in the outcomes
  • RemovedExercise Compliance RateTime frame: 12 Months
  • DescriptionMedication Adherence: how it is measured was reworded
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Active, not recruiting
    3 sites added, 2 sites removed
    Show 3 added (3 China)
    • Beijing Anzhen Hospital, Capital Medical University · Beijing, China
    • The First Hospital of Jilin University, Changchun, China · Changchun, China
    • The Second Affiliated Hospital of Nanchang University · Nanchang, China
    Show 2 removed
    • 13810720787 · Beijing, China
    • The First Hospital of Jilin University, Changchun, China · Jilin City, China
    Start date Jan 2026→Feb 27, 2026 (now actual)
    Primary completion Jul 2027→Oct 10, 2027
    Study completion Jul 2027→Oct 10, 2027
    Eligibility Maximum age 75 Years→80 Years; 1 inclusion criterion edited; 2 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedAge 18-7580 years
    Exclusion criteria
    • EditedHeart Failure: NYHA Class III-IV or LVEF < 4035%.
    • ChangedBefore Life expectancy < 1 year due to non-cardiovascular comorbiditiesNow Other serious comorbid conditions with a life expectancy of less than 1 year.
    • AddedPatients judged by the investigator to have poor adherence to the intervention.
    Secondary outcomes 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedExercise Compliance RateTime frame: 12 Months
    • DescriptionMedication Adherence: how it is measured was reworded
    + 4 other changes: verification date, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07332494
Responsible party
Chang sheng Ma (Director of cardiology department, Beijing Anzhen Hospital) — Principal investigator
First posted
Jan 12, 2026
Start date
Feb 27, 2026
Primary completion
Oct 10, 2027 (estimated)
Completion
Oct 10, 2027 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion